BeiGene (06160) Jumps Over 3% in Morning Trade as Company Raises Full-Year Revenue Guidance for Third Time This Year, Innovation Pipeline Nears Fruition

Stock News11-12

BeiGene (06160) shares climbed more than 3% in morning trading. As of press time, the stock was up 2.86% at HK$259, with turnover of HK$451 million.

On the news front, on November 5, BeiGene released its financial results, reporting revenue of RMB 34.993 billion for the first three quarters, up 26.8% year-on-year, while profit reached RMB 6.055 billion, soaring 431.8% year-on-year.

Buoyed by its strong performance in the first three quarters, BeiGene announced it has once again raised its operating performance forecast for the 2026 fiscal year, adjusting its full-year revenue guidance from "RMB 44.9 billion to RMB 46.2 billion" to a range of "RMB 46.3 billion to RMB 47 billion." Notably, this marks the company's third upward revision of its full-year guidance this year.

According to CITIC Securities, in the hematology oncology space, BRUKINSA's continued volume growth, the approval of new indications for sonrotoclax, and the potential filing of a marketing application for BTK CDAC together form multiple growth drivers. In the solid tumor space, core assets such as CDK4 inhibitors, B7-H4 ADCs, and GPC3 bispecific antibodies are densely entering Phase III registrational clinical trials, indicating a clear medium- to long-term growth trajectory. In our view, the company's fundamental performance continues to strengthen, and its innovation pipeline is about to enter a period of fruition, and we maintain a "Buy" rating.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment